Imaging CXCR4-related diseases using PET/CT
Official title: Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Run by Tianjin Medical University · NCT06690736 · Data updated 2026-11-12
This study is testing a new type of imaging to see if it can better identify and track diseases related to CXCR4 in patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 3 sites (Hefei, Anhui and 2 other locations) |
| Status | Recruiting |
| Started | March 1, 2022 |
| Main results expected | October 1, 2027 |
| Study ends | October 1, 2027 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT06690736 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with suspected or confirmed untreated lymphoproliferative and other CXCR4-related diseases.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or have a known allergy to Pentixafor may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with CXCR4-related diseases. Participants will undergo PET/CT imaging to assess the uptake of the tracer in lesions, with results analyzed for sensitivity, specificity, and accuracy. The goal is to determine how well this imaging technique can identify and monitor these diseases.
Why it matters
Potential benefit: If successful, this imaging technique could improve the diagnosis and monitoring of CXCR4-related diseases, leading to better patient outcomes.
How similar studies have gone: Other studies have shown promising results with similar imaging approaches, indicating potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients * 18F-FDG PET/CT within two weeks * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor
Where it's running
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China Recruiting -
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China Recruiting -
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients
This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.
-
Evaluating PET/CT for SSTR-related diseases
This study is testing a new type of PET/CT scan to see if it can help find cancer spots in adults who have tumors related to SSTR diseases.
-
Evaluating FAPI PET/CT for Diagnosing FAP-Related Diseases
This study is testing if a special type of scan can help find cancer in adults who have or might have tumors related to FAP.
-
68Ga-FAPI PET/CT imaging to detect primary and metastatic cancer lesions
This study tests whether 68Ga-DOTA/NOTA-FAPI-04 PET/CT can help find primary tumors and metastases in adults with various cancers.
-
Comparing two types of PET scans for cancer diagnosis
This study is testing whether a new type of PET scan can find cancer better than the standard scan in patients who have or might have tumors.
-
PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults
This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.